Condition: Non Small Cell Lung Cancer · NSCLC, Stage III · Nsclc · Sponsor: Maximilian Diehn
The purpose of this study is to test whether or not number of circulating cancer cells detected in the blood can be decreased the by combining the standard treatment (durvalumab) with Tremelimumab and additional chemotherapy
This description comes directly from the study's public registry record.
Rene Bonilla · 650-498-7703 · rbonilla@stanford.edu
Always discuss trial participation with your own doctor first.
| Stanford University | Stanford, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04585490